ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19.
ExeVir Bio and VIB-UGent’s bioRxiv pre-print reports on S2-binding camelid single-domain antibody-based drug, XVR013, that targets the Achilles’ heel in the SARS-CoV-2 viral spike Focus on protecting the millions of immuno-compromised patients, who are most vulnerable to COVID-19 Ghent, Belgium, 13 March 2023: ExeVir Bio, a biotech company developing robust single domain antibody therapies for broad […]
Read Post
Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554
Confo to receive upfront and milestone payments totaling $630M Company is eligible for up to $590M in additional milestones if Lilly proceeds with a second product candidate Tiered royalties payable to Confo on net sales Confo to have a co-investment option Ghent, Belgium – March 2, 2023 – Confo Therapeutics, a leader in the discovery […]
Read Post
Cellaion SA announces a total fundraising of EUR 23 million in 2022 for its phase IIB study in Acute on Chronic Liver Failure with Truffle Capital as lead investor in the final Closing followed by Newton Biocapital, Wallonie Entreprendre and individual investors.
Mont-Saint-Guibert, Belgium, 2023/01/13. Cellaïon is a biotechnology company based in Mont-St-Guibert, active in the field of cell therapy, an area of excellence in the life sciences industry in Wallonia. Its flagship product HepaStem®, in advanced clinical development, targets severe liver diseases, and in particular Acute on Chronic Liver Failure (ACLF). ACLF is an acute hepatic […]
Read Post
TargED Biopharmaceuticals announces the appointment of Erik van den Berg as Chair of its Supervisory Board
Utrecht, the Netherlands, January 19, 2023. TargED Biopharmaceuticals, a biotech spin-off of the University Medical Center Utrecht, announced today the appointment of Erik van den Berg as Chair and independent Board Member of its Supervisory Board. Erik holds a Master’s degree in Chemistry from the University of Utrecht, the Netherlands, and a MBA from Manchester […]
Read Post
Belgium: ExeVir lands European venture debt financing to develop novel nanobody COVID-19 therapy
ExeVir signs €25 million venture debt financing with European Investment Bank to develop a llama-derived nanobody COVID-19 therapeutic, labelled XVR012. Project expected to have important public health impact, addressing underserved therapeutics market for immunocompromised and elderly people. Venture debt financing is part of EIB’s COVID-19 response and is guaranteed by the InnovFin programme under the EU’s […]
Read Post
Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer
Mont Saint-Guibert, Belgium – December 27, 2022 – Novadip Biosciences SA (“Novadip” or “the Company”), a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs, today announced the appointment of Judy Ashworth, MD, as Chief Medical Officer of the Company. Dr. Ashworth brings deep experience and strong managerial […]
Read Post
Novadip Biosciences SA Announces Positive Results from Phase 1/2 Clinical Trial in Patients with Severe Bone Non-Union of the Lower Limb Following Trauma
Study results demonstrate NVD-003 has a favorable safety profile and convincing efficacy including rapid, durable bone healing in patients following failure of conventional treatment Clinical data will inform development of the Company’s autologous and allogeneic therapeutics for critical size bone defects and common orthopedic conditions First patient enrolled in Phase 1b/2a US/EU clinical trial in […]
Read Post
Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe9
The companies enter into a license agreement for the European rights to leriglitazone, currently under EMA review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD) Mataró, Barcelona (Spain) and Düsseldorf (Germany), November 10, 2022 – Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders and the […]
Read Post
Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million
Funding will support development of next generation orthopedic products that provide accelerated healing through single treatment cures Equity Funding led by CR-CP Life Science Fund, New Science Ventures, Fund+ and SRIW MONT SAINT-GUIBERT, BELGIUM – November 3, 2022 – Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative […]
Read Post
Coave Therapeutics Strengthens Board of Directors
Paris, France, October 20th, 2022 – Coave Therapeutics (‘Coave’), a biotech company leading the transition of genetic medicine from (ultra) rare to prevalent conditions in neurodegenerative diseases, today announces Frederic Chereau as Chairman of the Board and the appointment of Dr Claudia Mitchell, PhD, MBA to the Company’s Board of Directors as an independent non-executive […]
Read Post
ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors
Targeting final lead therapy selection, neutralizing all known previous and current SARS-CoV2 variants of concern by end 2022 Triple mode of action dengue fever program identified for development Industry veteran with exceptional leadership experience to support ExeVir’s new progressive pipeline against infectious diseases Ghent, Belgium, 20 Oct 2022: ExeVir is developing robust therapies providing broad protection […]
Read Post
Indigo Diabetes Announces First Participant Enrolled in the SHINE Clinical Trial
BELGIUM – Ghent, September 29, 2022 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of medical solutions using nanophotonics, today announces the enrollment of the first participant in Belgium in the SHINE clinical trial, which is designed to evaluate the longer-term stability of Indigo’s continuous multi-metabolite (‘CMM’) device. Indigo’s subcutaneously inserted CMM […]
Read Post
Dr Jeanne Bolger to chair Board of Directors of Belgium-based vaccine technology company AstriVax
Dr Jeanne Bolger brings over 35 years of management experience in the pharmaceutical industry to the new Belgium-based vaccine technology company. Last month, AstriVax closed its funding round – led by V-Bio Ventures and Fund+ – on 30 million euros. With this seed capital and the support of Dr Bolger, AstriVax will continue to build […]
Read Post
Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders
Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders Paris, France, September 14, 2022 – Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, announces it has entered into […]
Read Post
Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD
Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD) Mataró, Barcelona, Spain, September 14, 2022 – Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders, today announces that it has filed a Marketing Authorization Application (MAA) […]
Read Post
KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform
KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform Closing on € 30 million, AstriVax has raised the largest amount of seed capital in the history of spin-offs linked to Belgium-based university KU Leuven. The funding round was led by V-Bio Ventures and Fund+. The other investors are Flanders Future TechFund, Thuja […]
Read Post
Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium
Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium NEW YORK, Aug. 16, 2022 /PRNewswire/ — Immunic, Inc. (NASDAQ: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company has […]
Read Post
Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNABased Lead Candidate CDR132L in Heart Failure Patients PostMyocardial Infarction
Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNABased Lead Candidate CDR132L in Heart Failure Patients PostMyocardial Infarction Hanover, Germany, July 20, 2022 – Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the dosing of the first patient […]
Read Post
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén – Global Commercial Executive Brings 20 Years of Sales and Marketing Expertise – – Jan Van den Bossche Steps Down from Board After Six Year Tenure – NEW YORK , July 6, 2022 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company […]
Read Post
Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy
Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy. Funds will support the marketing authorization review process for male patients with AMN and launch preparations in Europe, as well as activities required for US approval pathway Proceeds will also cover activities for extension of indication to entire […]
Read Post
Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease
Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease – First Time Patients Will be Treated with the Company’s Orally Available Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium – NEW YORK, May 5, 2022 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a […]
Read Post
Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies
Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies MUNICH, GERMANY, May 3, 2022 – Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing […]
Read Post
Cellaïon announces update to its Board of Directors: Dr. Fouzia LAGHRISSI-THODE joins the biotech as Member of the Board
Cellaïon announces update to its Board of Directors: Dr. Fouzia LAGHRISSI-THODE joins the biotech as Member of the Board Mont-Saint-Guibert, Belgium, 29/03/2022: Cellaïon a Walloon biotechnology company developing Life saving advanced therapies to repair tissues and regenerate the liver today announced the following change to its Board of Directors. Highly experienced, Dr. Laghrissi-Thode has over […]
Read Post
Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain
Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain — Confo’s first drug candidate moves into clinical development — Ghent, Belgium – March 10, 2022 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first subjects […]
Read Post
Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity
– Initiated Enrollment in Phase 3 ENSURE Program of Vidofludimus Calcium for the Treatment of Relapsing Multiple Sclerosis; Final Cohort 2 Data from the Phase 2 EMPhASIS Trial Confirms Phase 3 Dose Selection – – Completed Enrollment of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis; Top-Line Data Expected in June of 2022 […]
Read Post